Close Menu

papers of note

After comparing manual methods with the firm's pcr.ai tool in more than 20,000 cases, they found that the use of AI improved test accuracy and reliability.

A study group eager to learn about genetic testing online was not won over by videos produced by academics without communication expertise.

The ongoing effort — called Your DNA, Your Say — based its results on responses from nearly 9,000 people from the US, UK, Canada, and Australia.

Researchers focused on using existing computational methods to fill in gaps in the human microbiome without reference genomes.

The Genes for Good Project has engaged 80,000 Facebook users via its online application and genotyped 27,000 people to date.

The test relies on a signature that Almac developed for stratifying breast cancer patients, but which, as the researchers showed, can be used in other cancers as well.

Informaticians at Spain's National Cancer Research Centre develop a methodology for evaluating likely drug efficacy based on specific patient genotypes.

The firm hopes the effort, recently described in the journal Oncotarget, will spur adoption of its testing services by oncologists, particularly in Europe, where it is determined to become a market leader.

The effort, which relied on Oxford BioDynamics' EpiSwitch platform, resulted in an assay that researchers believe could be developed into a test to guide therapy selection for patients.

Given the high yield of miRNA markers they were able to isolate, the researchers believe the approach could be commercialized for routine cancer testing.

Pages

Forensic genetic firm Verogen has bought the genetic genealogy site GEDmatch.

Researchers have 3D-printed plastic bunnies that encase the information needed to make more such bunnies in DNA, according to Discover magazine.

Dan Rather, the former CBS Evening News anchor and executive producer of a new documentary, writes at the Guardian that everyone needs to know about CRISPR.

In PNAS this week: analysis of FOXA1 upregulation in ER-positive breast cancer, gene editing to correct recessive dystrophic epidermolysis bullosa, and more.